Research programme: telomere signalling targeted agents - Pharminox

Drug Profile

Research programme: telomere signalling targeted agents - Pharminox

Alternative Names: PMX 500; PMX-000177; PMX-000177-761-785; RHPS4; TSTA - Pharminox

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cancer Research UK; University of Nottingham
  • Developer Pharminox
  • Class
  • Mechanism of Action Telomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in United Kingdom
  • 07 Dec 2011 Research programme: telomere signalling targeted agents - Pharminox is available for licensing as of 07 Dec 2011. http://www.pharminox.com
  • 16 Nov 2011 Pharmacodynamics data from a preclinical trial in Cancer presented at the 23rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2011)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top